Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth

References

• Geissmann F, Manz MG, Jung S, et al. Development of monocytes, macrophages, and dendritic cells. Science. 2010;327:656–661.
   PubMed Web of Science ®Google Scholar
• Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat Rev Immunol. 2017;17:349–362.
   PubMed Web of Science ®Google Scholar
• Brutkiewicz RR. Cell signaling pathways that regulate antigen presentation. J Immunol. 2016;197:2971–2979.
   PubMed Web of Science ®Google Scholar
• Li H, Shao S, Cai J, et al. Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. Immunology. 2017;152:462–471.
   PubMed Web of Science ®Google Scholar
• Kim JV, Latouche JB, Riviere I, et al. The ABCs of artificial antigen presentation. Nat Biotechnol. 2004;22:403–410.
   PubMed Web of Science ®Google Scholar
• Neal LR, Bailey SR, Wyatt MM, et al. The basics of artificial antigen presenting cells in T cell-based cancer immunotherapies. J Immunol Res Ther. 2017;2:68–79.
   PubMedGoogle Scholar
• Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun. 2009;388:621–625.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675–680.
   PubMed Web of Science ®Google Scholar
• Anwar MA, Shah M, Kim J, et al. Recent clinical trends in Toll-like receptor targeting therapeutics. Med Res Rev. 2019;39:1053–1090.
   PubMed Web of Science ®Google Scholar
• Smith M, Garcia-Martinez E, Pitter MR, et al. Trial watch: toll-like receptor agonists in cancer immunotherapy. Oncoimmunology. 2018;7:e1526250.
   PubMed Web of Science ®Google Scholar
• Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93:847–863.
   PubMed Web of Science ®Google Scholar
• Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system part II: role in immunity. Front Immunol. 2015;6:257.
   PubMed Web of Science ®Google Scholar
• Kullberg M, Martinson H, Mann K, et al. Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells. Nanomedicine. 2015;11:1355–1363.
   PubMed Web of Science ®Google Scholar
• Francian A, Mann K, Kullberg M. Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs. Int J Nanomedicine. 2017;12:5149–5161.
   PubMed Web of Science ®Google Scholar
• Francian A, Namen S, Stanley M, et al. Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. Nanomedicine. 2019;18:326–335.
   PubMed Web of Science ®Google Scholar
• Prins RM, Craft N, Bruhn KW, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006;176:157–164.
   PubMed Web of Science ®Google Scholar
• Whitmore MM, DeVeer MJ, Edling A, et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res. 2004;64:5850–5860.
   PubMed Web of Science ®Google Scholar
• Gatti-Mays ME, Balko JM, Gameiro SR, et al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019;5:37.
   PubMed Web of Science ®Google Scholar
• Luo Y, Zhou H, Krueger J, et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest. 2006;116:2132–2141.
   PubMed Web of Science ®Google Scholar
• Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77–92.
   PubMed Web of Science ®Google Scholar
• Madaan A, Verma R, Singh AT, et al. A stepwise procedure for isolation of murine bone marrow and generation of dendritic cells. J Biol Methods. 2014;1:e1.
   Google Scholar
• Sansom DM, Manzotti CN, Zheng Y. What’s the difference between CD80 and CD86? Trends Immunol. 2003;24:314–319.
   PubMed Web of Science ®Google Scholar
• Pan RY, Chung WH, Chu MT, Chen SJ, et al. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874.
   PubMed Web of Science ®Google Scholar
• Hamerman JA, Pottle J, Ni M, et al. Negative regulation of TLR signaling in myeloid cells-implications for autoimmune diseases. Immunol Rev. 2016;269:212–227.
   PubMed Web of Science ®Google Scholar
• Ning S, Pagano JS, Barber GN. IRF7: activation, regulation, modification and function. Genes Immun. 2011;12:399–414.
   PubMed Web of Science ®Google Scholar
• Dufour JH, Dziejman M, Liu MT, et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol. 2002;168:3195–3204.
   PubMed Web of Science ®Google Scholar
• Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22:189–195.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014;6:a016295.
   PubMed Web of Science ®Google Scholar
• Sun L, He C, Nair L, et al. Interleukin 12 (IL-12) family cytokines: Role in immune pathogenesis and treatment of CNS autoimmune disease. Cytokine. 2015;75:249–255.
   PubMed Web of Science ®Google Scholar
• Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010;20:87–103.
   PubMed Web of Science ®Google Scholar
• Anstadt EJ, Fujiwara M, Wasko N, et al. TLR tolerance as a treatment for central nervous system autoimmunity. J Immunol. 2016;197:2110–2118.
   PubMed Web of Science ®Google Scholar
• Herrera-Rivero M, Santarelli F, Brosseron F, et al. Dysregulation of TLR5 and TAM ligands in the Alzheimer’s brain as contributors to disease progression. Mol Neurobiol. 2019;56:6539–6550.
   PubMed Web of Science ®Google Scholar
• Hotz C, Treinies M, Mottas I, et al. Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses. Oncoimmunology. 2016;5:e1232219.
   PubMed Web of Science ®Google Scholar
• Nahid MA, Benso LM, Shin JD, et al. TLR4, TLR7/8 agonist-induced miR-146a promotes macrophage tolerance to MyD88-dependent TLR agonists. J Leukoc Biol. 2016;100:339–349.
   PubMed Web of Science ®Google Scholar
• Butcher SK, O'Carroll CE, Wells CA, et al. Toll-like receptors drive specific patterns of tolerance and training on restimulation of macrophages. Front Immunol. 2018;9:933.
   PubMed Web of Science ®Google Scholar